Minerva Neurosciences Inc (NERV)
Symbol Info
Listed Symbol NERV
Name Minerva Neurosciences Inc
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2017-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-1.29
Price Info
21 Day Moving Average $6.6443
21 Day EMA $6.625950
50 Day Moving Average $6.0006
50 Day EMA $6.394700
200 Day EMA $6.990070
200 Day Moving Average 7.181500
52 Week High $12.95
52 Week Low $4.07
52 Week Change $-22.069000
Alpha 0.005739
Beta 1.5223
Standard Deviation 0.196160
R2 0.072502
Periods 60
Share Information
10 Day Average Volume 297,415
20 Day Average Volume 280,576
30 Day Average Volume 302,692
50 Day Average Volume 922,677
Outstanding Shares 39,025,471
Float Shares 38,364,238
Percent Float 98.31%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 181
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 830,015
Institute Holdings Percent -
Institute Sold Previous 3 Months 3,121,041
Insider Holdings Date 2019-07-31
Insider Bought Previous 3 Months 6
Insider Holdings Percent 1.70%
Insider Sold Previous 3 Months 157,746
Insiders Shares Owned 661,233
Price Change
7 Day Price Change $-0.0599999
7 Day Percent Change -0.88%
21 Day Price Change $0.3000002
21 Day Percent Change 4.63%
30 Day Price Change $0.3900003
30 Day Percent Change 6.10%
Month To Date Price Change $0.1400
Month To Date Percent 2.11%
90 Day Price Change $0.500000
90 Day Percent Change 7.96%
Quarter To Date $1.150000
Quarter To Date Percent 20.43%
180 Day Price Change $-0.87
180 Day Percent Change -11.37%
200 Day Price Change $0.330000
200 Day Percent Change 5.12%
Year To Date $0.040000
Year To Date Percent 0.59%
Profile
Description Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. The company primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. Targeted disorders include schizophrenia, insomnia, major depressive disorder and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Details
Issue Type CS
Market Cap $264,592,693
Sec Type EQS
Auditor Deloitte & Touche LLP
Total Shares Outstanding 39,025,471
CEO Remy Luthringer
Employees 14
Last Audit UQ
Classification
CIK 0001598646
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 1601 Trapelo Road
Suite 286
Waltham, MA 2451
Website http://www.minervaneurosciences.com
Facisimile
Telephone +1 617 600-7373
Email wboni@minervaneurosciences.com
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $185,670,621
Price To Sales -
Price To Free Cash -6.4
PE High Last 5 Years -
Price To Book 3.8
Price To Cash Flow 80.3
PE Low Last 5 Years -
Price To Tangible Book 13.9
Financial Strength
Total Debt To Equity -
Int Coverage -170
Current Ratio 26.2
Leverage Ratio 1.5
Quick Ratio 25.2
Long Term Debt To Capital -
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -21.52
Return On Equity -31.97
Return On Capital -33.05
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
NERV
Minerva Ne..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.